Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.

< BACK TO ARCHIVE


Papers: 18 Dec 2021 - 24 Dec 2021


Human Studies

PAIN TYPE:
Migraine/Headache


2021 Dec 20


J Headache Pain


http://www.ncbi.nlm.nih.gov/pubmed/34930112?dopt=Abstract


22


1

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.

Authors

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
McAllister P, Lamerato L, Krasenbaum LJ, Cohen JM, Tangirala K, Thompson S, Driessen M, Casciano J, Dotiwala Z, Mauskop A
J Headache Pain. 2021 Dec 20; 22(1):156.
PMID: 34930112.

Abstract

Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are limited. This retrospective, observational cohort study assessed patient-reported migraine symptoms, health care resource utilization (HCRU), and direct medical costs before and after fremanezumab treatment initiation.
Read This Paper